RVMD · ISSUER CIK 1628171
Revolution Medicines, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 9 Revolution Medicines, Inc. insiders reported $0.00 of open-market purchases and $78.4M of sales on SEC Form 4.
↗9 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 19 of 19 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$78.4MInsider selling
−$78.4MNet open-market
Oct 28, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 202618:00 | Oct 26, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $186.99 | −2,310 | 39,765 | -5% | −$432K | ||
| Oct 28, 202618:00 | Oct 26, 2026 | RVMD | See Remarks | M · Exercise10b5-1 | $33.62 | +2,310 | 42,075 | +6% | $78K | ||
| Oct 1, 202618:00 | Sep 29, 2026 | RVMD | Chief Development Officer | S · Sell10b5-1 | $202.14 | −6,309 | 52,559 | -11% | −$1.3M | ||
| Oct 1, 202618:00 | Sep 29, 2026 | RVMD | Chief Development Officer | M · Exercise10b5-1 | $58.84 | +6,000 | 58,868 | +11% | $353K | ||
| Sep 29, 202618:00 | Sep 25, 2026 | RVMD | SVP & General Counsel | S · Sell10b5-1 | $207.32 | −765 | 51,776 | -1% | −$159K | ||
| Sep 28, 202618:00 | Sep 25, 2026from Sep 24, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $200.45 | −3,708 | 39,765 | -9% | −$743K | ||
| Sep 28, 202618:00 | Sep 25, 2026 | RVMD | See Remarks | M · Exercise10b5-1 | $33.62 | +3,121 | 42,886 | +8% | $105K | ||
| Sep 24, 202618:00 | Sep 22, 2026 | RVMD | Director | S · Sell10b5-1 | $193.04 | −10,143 | 4,333 | -70% | −$2.0M | ||
| Sep 24, 202618:00 | Sep 22, 2026 | RVMD | Director | M · Exercise10b5-1 | $1.12 | +5,070 | 14,476 | +54% | $6K | ||
| Sep 22, 202618:00 | Sep 18, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $196.94 | −1,764 | 40,352 | -4% | −$347K | ||
| Sep 18, 202618:06 | Sep 16, 2026 | RVMD | Chief Development Officer | S · Sell10b5-1 | $199.24 | −341 | 52,868 | -1% | −$68K | ||
| Sep 18, 202618:05 | Sep 16, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $199.24 | −1,774 | 42,116 | -4% | −$353K | ||
| Sep 18, 202618:04 | Sep 16, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $199.24 | −5,569 | 286,307 | -2% | −$1.1M | ||
| Sep 18, 202618:03 | Sep 16, 2026 | RVMD | Chief Operating Officer | S · Sell10b5-1 | $199.24 | −4,967 | 149,680 | -3% | −$990K | ||
| Sep 18, 202618:02 | Sep 16, 2026 | RVMD | See Remarks, Director | S · Sell10b5-1 | $199.24 | −13,988 | 253,342 | -5% | −$2.8M | ||
| Sep 18, 202618:01 | Sep 16, 2026 | RVMD | SVP & General Counsel | S · Sell10b5-1 | $199.24 | −3,366 | 52,541 | -6% | −$671K | ||
| Sep 18, 202618:00 | Sep 16, 2026 | RVMD | Chief Financial Officer | S · Sell10b5-1 | $199.24 | −4,053 | 119,216 | -3% | −$808K | ||
| Sep 15, 202618:00 | Sep 11, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $202.36 | −92,531 | 291,876 | -24% | −$18.7M | ||
| Sep 15, 202618:00 | Sep 11, 2026 | RVMD | See Remarks | M · Exercise10b5-1 | $41.71 | +92,531 | 384,407 | +32% | $3.9M | ||
| Sep 14, 202618:03 | Sep 10, 2026 | RVMD | See Remarks | S · Sell10b5-1 | $204.16 | −15,448 | 43,890 | -26% | −$3.2M | ||
| Sep 14, 202618:03 | Sep 10, 2026 | RVMD | See Remarks | M · Exercise10b5-1 | $33.62 | +9,363 | 59,338 | +19% | $315K | ||
| Sep 10, 202617:52 | Sep 8, 2026 | RVMD | Director | S · Sell10b5-1 | $209.82 | −17,090 | 0 | -100% | −$3.6M | ||
| Sep 2, 202616:30 | Aug 31, 2026 | RVMD | Director | S · Sell10b5-1 | $203.24 | −56,000 | 17,090 | -77% | −$11.4M | ||
| Aug 25, 202616:06 | Aug 21, 2026 | RVMD | General Counsel | S · Sell10b5-1 | $209.24 | −56,894 | 55,907 | -50% | −$11.9M | ||
| Aug 25, 202616:06 | Aug 21, 2026 | RVMD | General Counsel | M · Exercise10b5-1 | $20.00 | +56,280 | 112,801 | +100% | $1.1M | ||
| Aug 25, 202616:06 | Aug 21, 2026 | RVMD | See Remarks, Director | S · Sell10b5-1 | $209.20 | −86,000 | 267,330 | -24% | −$18.0M | ||
| Aug 25, 202616:06 | Aug 21, 2026 | RVMD | See Remarks, Director | M · Exercise10b5-1 | $4.73 | +80,000 | 347,330 | +30% | $378K |